Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications
2020; Lippincott Williams & Wilkins; Volume: 13; Issue: 6 Linguagem: Inglês
10.1161/circep.120.008688
ISSN1941-3149
AutoresOhad Oren, Eric H. Yang, Ty J. Gluckman, Erin D. Michos, Roger S. Blumenthal, Bernard J. Gersh,
Tópico(s)Pharmacological Receptor Mechanisms and Effects
ResumoHomeCirculation: Arrhythmia and ElectrophysiologyVol. 13, No. 6Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBUse of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular ImplicationsUnderstanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials Ohad Oren, Eric H. Yang, Ty J. Gluckman, Erin D. Michos, Roger S. Blumenthal and Bernard J. Gersh Ohad OrenOhad Oren Correspondence to: Bernard J. Gersh, MB, ChB, DPhil, MACC, Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester MN 55905. Email E-mail Address: [email protected] https://orcid.org/0000-0003-4700-8037 Division of Hematology and Oncology, Mayo Clinic, Rochester, MN (O.O.). , Eric H. YangEric H. Yang https://orcid.org/0000-0003-4889-7454 Division of Cardiology, Department of Medicine, University of California at Los Angeles (E.H.Y.). , Ty J. GluckmanTy J. Gluckman https://orcid.org/0000-0002-7187-6822 Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St Joseph Health, Portland, OR (T.J.G.). , Erin D. MichosErin D. Michos https://orcid.org/0000-0002-5547-5084 The Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD (E.D.M., R.S.B.). , Roger S. BlumenthalRoger S. Blumenthal https://orcid.org/0000-0003-1910-3168 The Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD (E.D.M., R.S.B.). and Bernard J. GershBernard J. Gersh https://orcid.org/0000-0001-5605-900X Department of Cardiovascular Medicine, Mayo Clinic & Mayo Clinic College of Medicine, Rochester, MN (B.J.G.). Originally published21 May 2020https://doi.org/10.1161/CIRCEP.120.008688Circulation: Arrhythmia and Electrophysiology. 2020;13:e008688Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: May 21, 2020: Ahead of Print The public health burden imposed by coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been substantial. As of May 5, 2020, >3.6 million individuals have been infected globally and >250 000 have died.1 Mounting research efforts are under way to test and develop effective prophylactics and therapeutics. Among the compounds under investigation are chloroquine and hydroxychloroquine, 2 widely used antimalarial drugs with additional indications for use in patients with connective tissue diseases and autoimmune disorders.Guided by in vitro evidence of antiviral activity and early clinical studies demonstrating improvements in surrogate end points, in the early weeks of the outbreak some prominent politicians, journalists, and physicians have advocated for the routine empirical use of these medications in patients with COVID-19 and for prophylaxis to prevent infection. While such an approach may seem reasonable given the current pandemic, it strongly contrasts with the standard modus operandi that demands supportive data from well-designed clinical trials before widespread medication use. In this article, we discuss the cardiovascular impact of chloroquine and hydroxychloroquine and provide our scientific opinion regarding the safety of these medications in patients with COVID-19 before formal regulatory review.Chloroquine and hydroxychloroquine are commonly prescribed worldwide. When used for malaria prophylaxis, chloroquine is generally administered at a dose of 500 mg per week starting 2 weeks before and continuing for up to 8 weeks following endemic exposure. Long-term use can be considered for the treatment of chronic autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. Hydroxychloroquine is typically prescribed as a 400 mg weekly dose when used for malaria chemoprophylaxis and as a 200 to 400 mg daily dose in patients with systemic lupus erythematosus or with rheumatoid arthritis.Mechanisms of ActionChloroquine and hydroxychloroquine alkalinize phagolysosomes, leading to impairment of cellular fusion and viral uncoating.2 The drug-mediated pH elevation also increases protease activity and decreases intracellular processing of secretory proteins, such as tumor necrosis factor α and interleukin-6, which are proinflammatory cytokines. This has prompted clinical investigation of tocilizumab, a humanized monoclonal antibody targeting interleukin-6, for which results are eagerly awaited. Specific antiparasitic mechanisms include inhibition of hemoglobin degradation in intraerythrocytic trophozoites, culminating in the accumulation of cytoxic heme and lysosome toxicity.3 Antiautoimmune activity stems from its activation of transcription factor FOXP3 (forkhead/winged helix transcription factor) and the promotion of regulatory T cells.Chloroquine and hydroxychloroquine have broad in vitro antiviral properties, prompting previous evaluation in HIV and the severe acute respiratory syndrome. In a primate cell model of the severe acute respiratory syndrome, both drugs inhibit terminal glycosylation of the cellular receptor, ACE2 (angiotensin-converting enzyme 2).4 Because blockade of ACE2 attenuates virus receptor binding pre- and post-infection, chloroquine and hydroxychloroquine are thought to be potentially effective options for viral prophylaxis and treatment.In SARS-CoV-2 cells, chloroquine suppresses viral entry and postentry stages, while promoting immune-modulating activity thought to be synergistic with its direct antiviral effects. In an in vitro pharmacokinetic model of SARS-CoV-2 infected cells, hydroxychloroquine appears to be more potent than chloroquine, with a significantly lower half maximal effective concentration (EC50=0.72 μmol/L, EC50=5.47 μmol/L).5 Azithromycin, whose combination with hydroxychloroquine is currently being evaluated in several trials, has multiple direct antiviral properties, with the most established mechanism being inhibition of interferon-stimulated gene expression and protein production.Clinical StudiesWhile a number of clinical trials are seeking to evaluate the effect of chloroquine and hydroxychloroquine in COVID-19, several have already been published. A summary of the most important studies with available results is included in Table.6,7,9–11 Although a few trials have demonstrated improvement in various surrogate end points (ie, viral clearance), these investigations are limited by small sample size. Importantly, this precludes adequate evaluation of safety and efficacy among diverse populations, including those with underlying cardiovascular disease.Table. Major Clinical Trials of Chloroquine or Hydroxychloroquine in Patients With COVID-19AuthorCountryStudy PopulationStudy SampleMedicationsEnd PointsResultsGautret et al6FranceHospitalized patients, age>12 y, SARS-CoV-2 positive PCR36HCQ±azithromycinViral clearance, nasopharyngeal swab, PCRViral-free: HCQ, 57%; HCQ+azithromycin: 100%Control: 12.5% (day 6)Chen et al7ChinaHospitalized patients, SARS-CoV-2 positive PCR30Arm A: HCQViral clearance, nasopharyngeal swab, PCRViral-free: HCQ, 87%Arm B: controlControl: 93% (P>0.05; day 7)Borba et al9BrazilHospitalized patients with clinically suspected COVID-1981Arm A: high-dose (600 mg twice daily for 10 days) chloroquineAll-cause mortality; QTc >500 msecMortality: high-dose, 39%; low-dose, 15%Arm B: low-dose (450 mg twice daily on day 1 and once daily for 4 days) chloroquine diphosphate.zQTc >500 msec: high-dose, 19%; low-dose, 11%Mahevas et al10FranceHospitalized adult patients, SARS-CoV-2 positive PCR, requiring oxygen181Arm A: HCQTransfer to ICU, all-cause mortality, within 7 daysAll-cause mortality: HCQ, 2.8%; control, 4.6% (nonsignificant)Arm B: controlTransfer to ICU or death: HCQ, 20%; control, 22% (nonsignificant)Chen et al11ChinaHospitalized adult patients, SARS-CoV-2 positive PCR62Arm A: HCQTime to clinical recoveryImprovement in pneumonia: HCQ, 81%; control, 55%Arm B: controlCOVID-19 indicates coronavirus disease 2019; HCQ, hydroxychloroquine; ICU, intensive care unit; and SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.Based predominantly on preclinical data, the US Food and Drug Administration issued an emergency use authorization of chloroquine phosphate in adults hospitalized with COVID-19 for whom clinical trial participation is not possible.12 The authorization statement recognizes that optimal dosing and treatment durations are currently unknown, and that high-quality clinical trial data are essential to understanding any therapeutic benefits. To date, only few clinical trials evaluating chloroquine and hydroxychloroquine have reported the cardiovascular safety of these medications when used to treat COVID-19. This is particularly important given the adverse cardiovascular effects, including cardiomyopathy, that have been reported previously. Both medications can induce cardiotoxicity via inhibition of lysosomal enzymes in cardiomyocytes, including α-galactosidase A, β-galactosidase, and arylsulfatase.13 These changes are reminiscent of the cardiomyopathy associated with Fabry disease, with biventricular concentric hypertrophy and diastolic dysfunction. At the ultrastructural level, hydroxychloroquine toxicity is associated with intracellular accumulation of myelin and formation of curvilinear bodies.14Chloroquine blocks the cardiac inward rectifier K+ current, IK1, and to a lesser degree the rapidly activating delayed rectifier, IKr, resulting in prolongation of the action potential. This increases the likelihood of ventricular ectopy and lethal ventricular arrhythmias. Hydroxychloroquine prolongs spontaneous action potential firing via inhibition of multiple cardiac channels, including that of ICaL and If.Chloroquine and hydroxychloroquine are also characterized by a number of additional adverse effects, including cutaneous (hyperpigmentation of skin), neuromuscular (weakness), and ophthalmologic (retinopathy) manifestations (Figure).Download figureDownload PowerPointFigure. Systemic adverse effects of chloroquine and hydroxychloroquine.To a large degree, the incidence and spectrum of adverse cardiovascular effects with chloroquine and hydroxychloroquine are not well described. Existing reports show that undifferentiated cardiac toxicity from these drugs appears to be more frequent in women (65%), typically following a long treatment duration (median of 7 years) and high cumulative dose.14 According to a systematic review of published cardiac complications with chloroquine and hydroxychloroquine (median duration of 7 years [range: 3 days–35 years]), conduction disorders were reported most commonly (85% of cases). Less frequently encountered cardiovascular effects included left ventricular hypertrophy, left ventricular hypokinesis and heart failure, QTc prolongation (especially in patients with preexisting QT prolongation and in combination with macrolide antibiotics), valvular heart disease, and pulmonary arterial hypertension.15 Interestingly, complete atrioventricular block was more commonly associated with chloroquine; whereas, left ventricular hypokinesis was more commonly encountered with hydroxychloroquine.A great deal of cardiovascular uncertainty exists when considering use of chloroquine or hydroxychloroquine in patients with COVID-19. First, historical trials that established the value of these medications in rheumatoid arthritis and systemic lupus erythematosus did not systematically collect cardiovascular safety data.16 Since electrocardiograms and cardiac imaging were not routinely performed, the incidence, risk factors, and clinical outcomes of cardiac arrhythmias or heart failure among patients receiving chloroquine or hydroxychloroquine are not known. In addition, the likelihood of recovery or response to neurohumoral blockade has also not been studied. Finally, while the potential for QTc prolongation is well known to occur with these medications, its incidence has not been established.This point is particularly relevant in patients with COVID-19, as both arrhythmias and cardiomyopathy have been described in those with more severe manifestations of the disease. Moreover, acutely ill patients with COVID-19 may be more likely to receive empirical antimicrobial regimens that include other QTc-prolonging drugs, such as azithromycin, levofloxacin, and azole antifungals. Azithromycin, in particular, has been recognized as a cause of QT prolongation and a higher risk of sudden cardiac death, which is more likely in women and in the elderly. Patients with severe COVID-19 also commonly manifest biochemical changes such as hypokalemia, hypomagnesemia, as well as fever, which can potentiate QT prolongation. In addition, although a recent randomized controlled trial showed no benefit with lopinavir/ritonavir compared with standard of care in patients with severe COVID-19,17 this combination therapy can interact with chloroquine, and may further prolong the QT interval.Collectively, these findings underscore the urgent need for additional studies formally assessing the arrhythmic potential of these agents through double-blind trial design and rigorous electrocardiographic monitoring protocols. Such an approach is feasible in the outpatient setting and in those already on telemetry. This is likely to be more challenging for those admitted to floors without telemetry services, as repeated electrocardiographic assessment increases exposure risk to healthcare workers. Therefore, a more pragmatic approach leveraging electrocardiographic assessment in permissive scenarios or in those at higher arrhythmia risk (concomitant proarrhythmic medications, underling cardiac disease). While preliminary data has been published evaluating the use of mobile cardiac telemetry for QTc and arrhythmia monitoring in patients with COVID-19 receiving medications with torsadogenic potential,18 additional studies are needed.A recent review from the Mayo Clinic outlines an approach to mitigating the torsadogenic potential of investigated pharmacotherapies for COVID-19.19 The article endorses the performance of a baseline ECG with QTc measurement for all patients with COVID-19 slated for treatment with medications which may lead to torsades des pointes. QTc intervals longer than the 99th percentile (470 msec in adult males, 480 msec in adult females) should be considered higher risk for ventricular arrhythmias and those with QTc intervals exceeding 500 ms should be regarded as higher risk for torsades des pointes as well as sudden cardiac death. In both groups, careful investigation of modifiable co-contributors to QTc prolongation should be mandated, with discontinuation of nonessential medications and close monitoring with telemetry.In late April, the Food and Drug Administration released a safety communication in which it cautioned against the use of chloroquine or hydroxychloroquine in patients with COVID-19 in a nonhospital, nontrial setting, due to the risk of serious arrhythmias. The Food and Drug Administration's safety statement followed reports of QT prolongation, ventricular tachycardia, and ventricular fibrillation in patients with COVID-19 treated with chloroquine or hydroxychloroquine with or without azithromycin.Effect on Left Ventricular FunctionThe incidence of cardiomyopathy with chloroquine and hydroxychloroquine is currently unknown, with most available data derived from case reports. Both medications, however, have been implicated as a cause and exacerbator of left ventricular diastolic dysfunction—a finding largely believed to be reversible upon drug discontinuation.20 There exists an important need to improve our understanding of the potential for cardiomyopathy in the midst of the COVID-19 pandemic. This is challenged by (1) the lack of pharmacovigilance and adverse event-focused studies to date, (2) marked differences between patients historically treated with these agents from those likely to be treated in the midst of an acute symptomatic viral infection, and (3) the added effect of the SARS-CoV-2 infection on the cardiovascular system. The potential for drug-induced valvular abnormalities, alterations to the conduction system, and left ventricular dysfunction, underscore the urgent need for dedicated studies to determine the prevalence, predisposing factors, and short- as well as long-term consequences.Prudent RecommendationsIn light of the potential for serious cardiovascular effects with chloroquine and hydroxychloroquine, we believe their use in COVID-19 should be limited to randomized controlled trials. For critically ill patients unable to enroll in a trial, selective in-hospital use could be considered, with careful clinical monitoring in keeping with the Food and Drug Administration's emergency use authorization.Empirically administering these drugs outside of a clinical trial risks exposing patients to serious adverse effects beyond those associated with COVID-19. Non evidence-based use may also limit their availability for patients with approved clinical indications (eg, systemic lupus erythematosus, rheumatoid arthritis). Of key importance is the need for condition-specific pharmacotoxicity analyses and trial safety reporting (Figure).In summary, findings regarding the benefit of chloroquine/hydrochloquine have not been encouraging to date, but larger trials are underway to assess the efficacy, and in particular the efficacy related to timing of drug administration. There exists an urgent need to enroll patients in clinical trials that are able to identify rare, but important adverse cardiovascular events. Studies evaluating chloroquine and hydroxychloroquine should systematically collect baseline demographic data, results from electrocardiographic and echocardiographic monitoring before and during treatment, and rates of adverse cardiovascular events in both the short- and long-term. Only with such an approach will the safety of these agents be truly understood.Nonstandard Abbreviations and AcronymsACE2angiotensin-converting enzyme 2COVID-19coronavirus disease 2019FOXP3forkhead/winged helix transcription factorSARS-CoV-2severe acute respiratory syndrome coronavirus 2Sources of FundingNone.DisclosuresB.J. Gersh is CRO for Trials involving Edwards Percutaneous Valve Devices: Baim Institute; DSMB—REPRISE Study: Boston Scientific Corporation, DSMB—RELIEVE-HF & SPYRAL Trials: Cardiovascular Research Foundation, DSMB—Pioneer HCM: Duke Clinical Research Institute, DSMB: Duke University, ENVISAGE-TAVI DSMB: Icahn School of Medicine at Mount Sinai, Executive Committee ORBIT Registries; Chairman DSMB; Steering Committee & Writing Committee (REVEAL Trial): Janssen Scientific Affairs (DSMB—PROMINENT Trial Medtronic Inc); Kowa Research Institute, Inc, DSMB— General Consulting: MyoKardia, Steering Committee—Garfield Study: Thrombosis Research Institute. The other authors report no conflicts.FootnotesFor Sources of Funding and Disclosures, see page 590.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to: Bernard J. Gersh, MB, ChB, DPhil, MACC, Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester MN 55905. Email Gersh.Bernard@mayo.eduReferences1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time.Lancet Infect Dis. 2020; 20:533–534. doi: 10.1016/S1473-3099(20)30120-1CrossrefMedlineGoogle Scholar2. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century.Int J Antimicrob Agents. 2007; 30:297–308. doi: 10.1016/j.ijantimicag.2007.05.015CrossrefMedlineGoogle Scholar3. Sullivan DJGluzman IY, Russell DG, Goldberg DE. On the molecular mechanism of chloroquine's antimalarial action.Proc Natl Acad Sci U S A. 1996; 93:11865–11870. doi: 10.1073/pnas.93.21.11865CrossrefMedlineGoogle Scholar4. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.Virol J. 2005; 2:69. doi: 10.1186/1743-422X-2-69CrossrefMedlineGoogle Scholar5. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, et al. In vitroantiviralactivity and projection of optimizeddosingdesign of hydroxychloroquine for the treatment of severeacuterespiratorysyndromecoronavirus 2 (SARS-CoV-2).Clin Infect Dis. 2020;ciaa237. doi: 10.1093/cid/ciaa237CrossrefMedlineGoogle Scholar6. Gautret P, Lagier JC, Parola P, Honag VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [published online ahead of print, 2020 Mar 20].Int J Antimicrob Agents. 2020;105949. doi: 10.1016/j.ijantimicag.2020.105949CrossrefMedlineGoogle Scholar7. Chen J, Liu D, Liu L, Ping L, Qingnian XU, Lu X, Yun L, Dan H, Shuli S, Dandan Z, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19).J XheJiang Univ. 2020; 49:215–219.Google Scholar8. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.Biosci Trends. 2020; 14:72–73. doi: 10.5582/bst.2020.01047CrossrefMedlineGoogle Scholar9. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mourão MPG, Brito-Sousa JD, Baía-da-Silva D, Guerra MVF, et al; CloroCovid-19 Team. Effect of high vs lowdoses of chloroquinediphosphate as adjunctivetherapy for patientshospitalizedwithsevereacuterespiratorysyndromecoronavirus 2 (SARS-CoV-2) infection: a Randomized Clinical Trial.JAMA Netw Open. 2020; 3:e208857. doi: 10.1001/jamanetworkopen.2020.8857CrossrefGoogle Scholar10. Mahevas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, Gallien S, Lepeule R, Szwebel T, Lescure X, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial.medRxiv. 2020;04.10.20060699. doi: 10.1101/2020.04.10.20060699Google Scholar11. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, Zhang Z. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial.medRxiv. 2020;03.22.20040758. doi: 10.1101/2020.03.22.20040758Google Scholar12. Fact Sheet for health care providers. Emergency use authorization (EUA) of chloroquine phosphate supplied from the strategic national stockpile for treatment of COVID-19 in certain hospitalized patients. U.S Food and Drug Administration (FDA).https://www.fda.gov/media/136535/download. Accessed April 3, 2020Google Scholar13. Frustaci A, Morgante E, Antuzzi D, Russo MA, Chimenti C. Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy.Int J Cardiol. 2012; 157:117–119. doi: 10.1016/j.ijcard.2012.03.112CrossrefMedlineGoogle Scholar14. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complicationsattributed to chloroquine and hydroxychloroquine: asystematicreview of the literature.Drug Saf. 2018; 41:919–931. doi: 10.1007/s40264-018-0689-4CrossrefMedlineGoogle Scholar15. Stas P, Faes D, Noyens P. Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine.Int J Cardiol. 2008; 127:e80–e82. doi: 10.1016/j.ijcard.2007.04.055CrossrefMedlineGoogle Scholar16. Tye MJ, White H, Appel B, Ansell HB. Lupus erythematosus treated with a combination of quinacrine, hydroxychloroquine and chloroquine.N Engl J Med. 1959; 260:63–66. doi: 10.1056/NEJM195901082600203CrossrefMedlineGoogle Scholar17. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Son B, Cai Y, Wei M, et al. A yrial of lopinavir-ritonavir in adultshospitalized with severe Covid-19. [published online ahead of print, 2020 Mar 18]N Engl J Med. 2020; 382:1787–1799. doi: 10.1056/NEJMoa2001282CrossrefMedlineGoogle Scholar18. Chang D, Saleh M, Gabriels J, Ismail H, Goldber B, Willner J, Beldner S, Mitra R, John R, Epstein LM. Inpatient use of ambulatorytelemetrymonitors for COVID-19 patientstreated with hydroxychloroquine and/or azithromycin. [published online ahead of print, 2020 Apr 18]J Am Coll Cardiol. 2020;S0735-1097(20)35009-9. doi: 10.1016/j.jacc.2020.04.032MedlineGoogle Scholar19. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent Guidance for Navigating and Circumventing the QTc Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for COVID-19.Mayo Clinic Proceedings.2020;95. https://www.mayoclinicproceedings.org/article/S0025-6196(20)30313-X/pdf. Accessed May 29, 2020.Google Scholar20. Yogasundaram H, Hung W, Paterson ID, Sergi C, Oudit GY. Chloroquine-induced cardiomyopathy: a reversible cause of heart failure.ESC Heart Fail. 2018; 5:372–375. doi: 10.1002/ehf2.12276CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Jantan I, Arshad L, Septama A, Haque M, Mohamed‐Hussein Z and Govender N (2022) Antiviral effects of phytochemicals against severe acute respiratory syndrome coronavirus 2 and their mechanisms of action: A review, Phytotherapy Research, 10.1002/ptr.7671, 37:3, (1036-1056), Online publication date: 1-Mar-2023. Liu C, Lin F, Chen Y, Lin Y, Lu Y, Chan C, Higa S, Chen S and Chen Y (2023) Modulation of post-pacing action potential duration and contractile responses on ventricular arrhythmogenesis in chloroquine-induced long QT syndrome, European Journal of Pharmacology, 10.1016/j.ejphar.2023.175493, 941, (175493), Online publication date: 1-Feb-2023. Burkhardt A, Lu A, Asante I and Louie S (2023) Pharmacologic Therapeutics for COVID‐19 Coronavirus Disease 2019 (COVID‐19), 10.1002/9781119789741.ch13, (290-318), Online publication date: 6-Jan-2023. Mitjà O, Reis G, Boulware D, Spivak A, Sarwar A, Johnston C, Webb B, Hill M, Smith D, Kremsner P, Curran M, Carter D, Alexander J, Corbacho M, Lee T, Hullsiek K, McDonald E, Hess R, Hughes M, Baeten J, Schwartz I, Metz L, Richer L, Chew K, Daar E, Wohl D and Dunne M (2023) Hydroxychloroquine for treatment of non‐hospitalized adults with COVID ‐19: A meta‐analysis of individual participant data of randomized trials , Clinical and Translational Science, 10.1111/cts.13468 Chang X, Ismail N, Rahman A, Xu D, Chan R, Ong S and Ong S (2022) Long COVID-19 and the Heart: Is Cardiac Mitochondria the Missing Link?, Antioxidants & Redox Signaling, 10.1089/ars.2022.0126 Gagnon L, Sadasivan C, Yogasundaram H and Oudit G (2022) Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic, Current Heart Failure Reports, 10.1007/s11897-022-00581-y, 19:6, (458-466), Online publication date: 1-Dec-2022. Satterfield B, Bhatt D and Gersh B (2021) Cardiac involvement in the long-term implications of COVID-19, Nature Reviews Cardiology, 10.1038/s41569-021-00631-3, 19:5, (332-341), Online publication date: 1-May-2022. El Kadri M, Al Falasi O, Ahmed R, Al Awadhi A, Altaha Z, Hillis A, Panikkaveetil B, Abdalla S, Ansel Benette H, Almubarak A, Saifuddin M, Alattar Y, Oulhaj A and AlKaabi S (2022) Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study, BMJ Open, 10.1136/bmjopen-2021-051579, 12:2, (e051579), Online publication date: 1-Feb-2022. Desmarais J, Rosenbaum J, Costenbader K, Ginzler E, Fett N, Goodman S, O'Dell J, Pineau C, Schmajuk G, Werth V, Link M and Kovacs R (2021) American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity, Arthritis & Rheumatology, 10.1002/art.41934, 73:12, (2151-2160), Online publication date: 1-Dec-2021. Zou H, Yang Y, Dai H, Xiong Y, Wang J, Lin L and Chen Z (2021) Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment, Frontiers in Pharmacology, 10.3389/fphar.2021.732403, 12 Li J, Zhang Y, Li L, Yi W, Hao Y and Bi Y (2021) Predictive Analysis of Factors Influencing Depression Status of Nurses in the COVID-19 Pandemic Intensive Care Unit, Frontiers in Psychiatry, 10.3389/fpsyt.2021.596428, 12 Afshar Z, Babazadeh A, Janbakhsh A, Bayani M, Ramezani E, Khaneshan A and Ebrahimpour S (2021) A review of cardiovascular involvements associated with medications used to treat COVID-19 infection, Cor et Vasa, 10.33678/cor.2020.073, 63:3, (359-363), Online publication date: 20-Jul-2021. Tonk M, Růžek D and Vilcinskas A (2021) Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2, Viruses, 10.3390/v13050912, 13:5, (912) Vibhute P, Jadhav S, Dake S and Dawane B A Mini Review: Origin, Treatments, Preventions, Real Facts and Viability of the Recent Pandemic of Novel Coronavirus-2019, Coronaviruses, 10.2174/2666796701999200826114852, 2:5, (9-14) Manchanda K, Singh J, Bhagat R, Tiwana I and Singh H Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective, International Journal of Risk & Safety in Medicine, 10.3233/JRS-200060, 32:1, (3-17) Chee Y, Tan S and Yeoh E (2020) Dissecting the interaction between COVID‐19 and diabetes mellitus, Journal of Diabetes Investigation, 10.1111/jdi.13326, 11:5, (1104-1114), Online publication date: 1-Sep-2020. Yasmin Kusumawardhani N, Huang I, Martanto E, Sihite T, Nugraha E, Prodjosoewojo S, Hamijoyo L and Hartantri Y (2020) Lethal Arrhythmia ( Torsade de Pointes ) in COVID-19: An Event Synergistically Induced by Viral Associated Cardiac Injury, Hyperinflammatory Response, and Treatment Drug? , Clinical Medicine Insights: Case Reports, 10.1177/1179547620972397, 13, (117954762097239), Online publication date: 1-Jan-2020. June 2020Vol 13, Issue 6 Advertisement Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCEP.120.008688PMID: 32436730 Originally publishedMay 21, 2020 KeywordschloroquineCOVID-19hydroxychloroquinepandemictrophozoitesPDF download Advertisement SubjectsArrhythmiasSudden Cardiac Death
Referência(s)